rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Amphastar Pharmaceuticals, Inc.

AMPH · Nasdaq

Health CarePharmaceuticalsJust started moving

AMPH stood above a rising 150-day average in 15 of the last 52 weekly readings, including each of the last 2 weeks. It is 23.1% above that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
2 in a row
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$2.5M
Officials’ trades on record
0
Institutions holding
189 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months11
Buyers · sellers0 · 4
WhoDidSharesTraded
William J. PetersCFO, EVP & TREASURERsold4,139at $25.0021 Sep 2026filed 23 Sep 2026
Rong ZhouSENIOR EVP, PRODUCTION CENTERsold10,000at $23.9416 Sep 2026filed 17 Sep 2026
Rong ZhouSENIOR EVP, PRODUCTION CENTERsold3,187at $23.632 Sep 2026filed 3 Sep 2026
Richard K. PrinsDirectorsold7,973at $20.3011 Aug 2026filed 12 Aug 2026
William J. PetersCFO, EVP & TREASURERsold8,180at $22.487 Aug 2026filed 11 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders189-2 on the quarter
New · exited33 · 34
Reported value$544.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.reduced · filed 7 Aug 20265,224,934$105.4M-196,409−3.6%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20262,305,107$46.5M+277,160+13.7%
STATE STREET CORPadded · filed 7 Aug 20261,642,126$33.1M+34,611+2.2%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,481,952$29.9M-61,703−4.0%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 20261,176,626$23.7M+159,088+15.6%
MARSHALL WACE, LLPadded · filed 13 Aug 20261,066,322$21.5M+40,682+4.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026969,840$19.6M-6,810−0.7%
FULLER & THALER ASSET MANAGEMENT, INC.reduced · filed 12 Aug 2026949,238$19.2M-445,901−32.0%
D. E. Shaw & Co., Inc.added · filed 14 Aug 2026887,048$17.9M+221,506+33.3%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026809,568$16.3M+21,752+2.8%
31 Mar 2023 – 30 Jun 2026
174207240Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

William J. Peters Company insiderCFO, EVP & TREASURER · last 21 Sep 20260 · 57
Rong Zhou Company insiderSENIOR EVP, PRODUCTION CENTER · last 16 Sep 20260 · 36
Richard K. Prins Company insiderDirector · last 11 Aug 20262 · 44
Anthony T. Pierce Company insiderDirector · last 9 Jul 20260 · 0
Howard Lee Company insiderDirector · last 2 Jun 20261 · 18
David Russell Gaugh Company insiderDirector · last 1 Jun 20260 · 0
Diane G. Gerst Company insiderDirector · last 1 Jun 20260 · 19
Gayle Deflin Company insiderDirector · last 1 Jun 20260 · 3
Michael A. Zasloff Company insiderDirector · last 1 Jun 20261 · 18
Jack Y. Zhang Company insiderCEO & CHIEF SCIENTIFIC OFFICER · last 15 Mar 20262 · 30
Yakob Liawatidewi Company insiderEVP CORP ADMIN CENTER · last 15 Mar 20260 · 33
Mary Z. Luo Company insiderCOO, Chief Scientist, Chairman · last 6 Mar 20260 · 16

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202549.5%
Operating profit marginFY 2025 · to 31 Dec 202519.5%
Free cash flow marginFY 2025 · to 31 Dec 202516.8%
Return on capital employedFY 2025 · to 31 Dec 20259.5%
Cash conversionFY 2025 · to 31 Dec 2025159%
Debt to equityFY 2025 · to 31 Dec 20250.79×
Research spendFY 2025 · to 31 Dec 202511.9%
Share count trendFY 2025 · to 20 Feb 2026-0.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$170.2M
Free cash flowFY 2025 · to 31 Dec 2025$121.2M

Analyst forecasts

No analyst forecasts yet.